Clinical trials: Cytomegalovirus Prophylaxis
Kidney Transplantation, CMV Infection
Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection
CMV infection in transplantation remains the most frequent infectious complication causing increased morbidity and mortality. International recommendations advocate prevention of this infection by instituting direct antiviral…
- Trial name
- SYNTAGME (NCT04934527)
- Testing
- Cytotect
- Where
- France
- Volunteers
- 42 people
- Sponsor
- University Hospital, Bordeaux
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Cytomegalovirus Infection
Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV
The objectives of this first-in-human is to evaluate the safety and the immunogenicity of three administrations of a bivalent vaccine candidate against human cytomegalovirus, at three different dose levels.
- Trial name
- NCT02798692
- Testing
- Low dose HB-101, Medium dose HB-101, High dose HB-101
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hookipa Biotech GmbH
Cytomegalovirus Infections
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
This study will determine the relative efficacy and safety of up to 100 days Valcyte prophylaxis relative to up to 200 days Valcyte prophylaxis when given for the prevention of CMV disease in high-risk (D+/R-) kidney allograft…
- Trial name
- IMPACT (NCT00294515)
- Testing
- Valganciclovir
- Where
- 80 sites in United States, Australia and 11 more
- Volunteers
- 326 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus Viraemia
Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients
This study will evaluate whether a test for Cytomegalovirus (CMV) specific cell-mediated immunity can be used to determine whether patients who complete a course of therapy for CMV viremia need secondary antiviral prophylaxis.
- Trial name
- Q-CMV (NCT02370758)
- Testing
- Valganciclovir or Ganciclovir
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University Health Network, Toronto
Chronic Lymphocytic Leukemia, Leukemia
Oral Valganciclovir Versus Valacyclovir
To determine if the rate of cytomegalovirus reactivation during treatment with alemtuzumab (Campath) is reduced by the use of valganciclovir prophylaxis.
- Trial name
- NCT00562770
- Testing
- Valganciclovir, Valacyclovir
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Patients Who Have Received Allo-HSCT
Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this study is to determine whether nilotinib is effective in the prophylaxis and treatment of CMV reactivation in allo-HSCT patients.
- Trial name
- NCT01252017
- Testing
- nilotinib
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- National Taiwan University Hospital
Cytomegalovirus Cell Mediated Immunity, Stem Cell Transplantation, Hematopoietic
Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)
Cytomegalovirus (CMV) infection is a common complication in patients undergoing hematopoietic stem cell transplantation (SCT). Fixed-duration letermovir (LTV) prophylaxis during the first 100 days post-SCT is effective and safe…
- Trial name
- INMUNOEND (NCT06814301)
- Testing
- Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
- Where
- Spain
- Volunteers
- 123 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
Cytomegalovirus Infections
A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients
This is a Phase II, randomized, double-blind, placebo-controlled study designed to assess the safety and clinical activity of multiple intravenous doses of MCMV5322A/MCMV3068A in cytomegalovirus (CMV)-seronegative recipients of a…
- Trial name
- NCT01753167
- Testing
- MCMV3068A, MCMV5322A
- Where
- 39 sites in United States, Belgium and 6 more
- Volunteers
- 122 people
- Sponsor
- Genentech, Inc.
Cytomegalovirus Infections
Comparison of Safety and Efficacy of de Novo Everolimus
Nowadays, de novo everolimus regimen in renal transplant patients is considered for reduction of cyclosporine dose and it is mentioned that this regimen not only has similar safety and efficacy, but also could prevent…
- Trial name
- NCT04906304
- Testing
- Everolimus Pill, Sandimmun (Neoral) dose plus cellcept
- Where
- Iran
- Volunteers
- 35 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Infection in Solid Organ Transplant Recipients
Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
The objective of the present study is to optimize intravenous ganciclovir(GCV) and oral valganciclovir (VGCV)doses, advised by the drug exposure, indicated by the area under the concentration time curve (AUC), in renal transplant…
- Trial name
- NCT01446445
- Testing
- Ganciclovir/ Valganciclovir according to SPC, Ganciclovir/ Valganciclovir according to PK model
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Nuria Lloberas
Cytomegalovirus Infections
The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised Trial
21 patients were randomised to receive instructions and coaching or no intervention on the use and intake of ganciclovir. Intake of medication was measured by an electronic pill box. The duration of the study was 100 days.
- Trial name
- NCT00566072
- Testing
- instructions and coaching
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- University Hospital, Ghent
Kidney Transplant, Liver Transplant
Letermovir for R+ Study
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been…
- Trial name
- MISP CMV (NCT07706166)
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- University of Wisconsin, Madison
Evaluate the Effectiveness of CMV Prevention Strategies in Kidney Transplant Recipients
Use of Tacrolimus and MTOR Inhibitors With Anticipatory Therapy vs. Tacrolimus and Mycophenolic Acid With Universal Prophylaxis in Renal Recipients at High Risk of Posttransplant Cytomegalovirus.
The overall objective of this project is to optimise preventive treatment of CMV infection/disease in renal transplant recipients at increased risk of CMV post-transplantation.
- Trial name
- NCT07203664
- Testing
- steroids, tacrolimus and mTOR inhibitors, steroids, tacrolimus and mycophenolic acid.
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario La Paz
Cytomegalovirus Infections
Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients
Cytomegalovirus (CMV) infection remains one of the most frequent infectious complications after kidney transplantation. In intermediate-risk recipients (seropositive, R+ recipient) of living donor kidney transplants, optimal…
- Trial name
- (PREVAIL-KT) (NCT07430683)
- Testing
- Valganciclovir Prophylaxis, Preemptive Therapy (CMV PCR Monitoring)
- Where
- Mexico
- Volunteers
- 68 people
- Sponsor
- University of Guadalajara
CMV Infection or Reactivation After Allogenic HSCT
The Comparison the CMV Infection and Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation Between Standard Regimen, Methotrexate Plus Cyclosporin A, and Post-transplant Cyclophosphamide-based Regimen
The goal of this observational study is to compare the CMV infection and reactivation after allogeneic hematopoietic stem cell transplantation Between Standard Regimen, Methotrexate plus Cyclosporin A, and Post-transplant…
- Trial name
- CMV (NCT06362720)
- Volunteers
- 158 people
- Sponsor
- Siriraj Hospital
Viral Infection
ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus
The subjects eligible for this trial have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- ARMS (NCT01570283)
- Testing
- Multivirus-specific T cells Dose Level 1, Multivirus-specific T cells Dose Level 2, Multivirus-specific T cells Dose Level 3
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- AlloVir
Cytomegalovirus Infections
Breakthrough CMV Lung Transplant -Multicentre
Cytomegalovirus (CMV) infection is the most common opportunistic infection in lung transplantation leading to direct and indirect effects that can result in life threatening complications.
- Trial name
- NCT04439916
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Alberta